Your browser doesn't support javascript.
loading
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa, Shingo; Zenke, Yoshitaka; Taki, Tetsuro; Aokage, Keiju; Sakai, Tetsuya; Shibata, Yuji; Izumi, Hiroki; Nosaki, Kaname; Umemura, Shigeki; Matsumoto, Shingo; Yoh, Kiyotaka; Sakamoto, Naoya; Sakashita, Shingo; Kojima, Motohiro; Tsuboi, Masahiro; Goto, Koichi; Ishii, Genichiro.
Afiliação
  • Kitagawa S; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Zenke Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Taki T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
  • Aokage K; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
  • Sakai T; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Shibata Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Izumi H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Nosaki K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Umemura S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Matsumoto S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Sakamoto N; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
  • Sakashita S; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
  • Kojima M; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
  • Tsuboi M; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
  • Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Ishii G; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: gishii@east.ncc.go.jp.
Lung Cancer ; 188: 107453, 2024 02.
Article em En | MEDLINE | ID: mdl-38160515
ABSTRACT

OBJECTIVES:

This study extracted clinicopathological features associated with recurrence and evaluated the tumor microenvironment in consecutive cases with resected pathological stage II-III epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (EGFR-mt).

METHODS:

Between January 2008 and November 2018, we retrospectively reviewed 387 consecutive patients with pathological stage II-III lung adenocarcinoma who underwent surgical resection. We examined the EGFR mutation status (wild-type or mutant) and the evaluated clinicopathological features of all patients. In addition, tumor-promoting cancer-associated fibroblasts (CAFs), tumor-associated M2 macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment of EGFR-mt cells were evaluated by immunohistochemical analysis.

RESULTS:

EGFR-mt (n = 124, 32 %) had more lymph node and pulmonary metastases than EGFR-wild-type lung adenocarcinoma (EGFR-wt) despite the smaller invasive component size. The disease-free survival (DFS) of patients with EGFR-mt tended to be shorter than that of patients with EGFR-wt. In the analysis according to the predominant subtype, EGFR-mt with papillary-predominant subtype had a significantly shorter 5-year DFS than that of EGFR-wt with papillary-predominant subtype (15.3 % vs. 44.1 %, p < 0.01). We observed no significant differences among the other subtypes. Multivariate analysis of DFS in patients with EGFR-mt revealed that male sex, pathological stage III, lymph node metastasis, pulmonary metastasis in the same lobe and non-acinar and non-lepidic predominant subtypes (papillary, solid, or micropapillary) were independent poor prognostic factors. Immunohistochemical analysis of EGFR-mt revealed that non-acinar- and non-lepidic-predominant subtypes were associated with a higher frequency of podoplanin-positive CAFs (36 % vs. 13 %, p = 0.01) and a higher median number of CD204-positive TAMs (61 vs. 49, p = 0.07) compared to the acinar- or lepidic-predominant subtypes.

CONCLUSIONS:

Non-acinar and non-lepidic predominant subtypes were predictors of recurrence and had an aggressive tumor microenvironment in pathological stage II-III EGFR-mt.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Adenocarcinoma de Pulmão / Neoplasias Pulmonares Limite: Humans / Male Idioma: En Revista: Lung Cancer Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Adenocarcinoma de Pulmão / Neoplasias Pulmonares Limite: Humans / Male Idioma: En Revista: Lung Cancer Ano de publicação: 2024 Tipo de documento: Article